Explore

Rapid Read Rapid Read
FNIH Honors Dan Doctoroff, Biogen, and NIAMS with 2026 Charles A. Sanders, MD, Partnership Award for Biomedical Research Contributions

FNIH Honors Dan Doctoroff, Biogen, and NIAMS with 2026 Charles A. Sanders, MD, Partnership Award for Biomedical Research Contributions

The Foundation for the National Institutes of Health (FNIH) has announced the recipients of the 2026 Charles A. Sanders, MD, Partnership Award. The award will be presented to Dan Doctoroff, founder of Target ALS, Biogen, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for their significant contributions to advancing biomedical research. Dan Doctoroff is recognized for his role in the Accelerating Medicines Partnership (AMP) Amyotrophic Lateral Sclerosis (ALS) program, which has initiated the ALS Knowledge Portal, a major data source for ALS research. Biogen is acknowledged for its 15-year partnership with FNIH, supporting various initiatives in immunology and neuroscience. NIAMS is honored for its leadership in the AMP program, which aims to transform the development of new diagnostics and treatments. The awards will be presented at the 14th Annual FNIH Awards Ceremony on October 28, 2026, in Washington, D.C.
Rapid Read Rapid Read
Allen Institute Advances Genetic Therapy for Brain Disorders with New Accelerator

Allen Institute Advances Genetic Therapy for Brain Disorders with New Accelerator

The Allen Institute in Seattle has launched the Brain Health accelerator, a collaborative initiative aimed at developing genetic therapies for brain disorders such as Alzheimer's, Parkinson's, ALS, and Huntington's disease. This effort is part of the broader BRAIN Initiative, a public-private partnership initiated in 2013 to advance brain research and treatment development. The accelerator seeks to translate scientific knowledge about the brain into practical treatments by leveraging genetic therapies, including gene editing. Scientists at the Allen Institute have made significant progress in understanding the genetic underpinnings of brain cells, which is crucial for developing precision therapies. The initiative is attracting researchers like Jeff Carroll, who is focused on Huntington's disease, a condition he has a personal connection to. The accelerator's approach allows for large-scale research efforts that smaller labs cannot achieve alone.
Rapid Read Rapid Read
Advancements in Lupus Treatment Unveiled at EULAR Conference

Advancements in Lupus Treatment Unveiled at EULAR Conference

The European Alliance of Associations for Rheumatology (EULAR) conference in London showcased promising new treatments for systemic lupus erythematosus (SLE). Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran are among the drugs showing potential in clinical trials. Nipocalimab, an FcRn inhibitor, demonstrated significant disease activity reduction in the JASMINE study. Dapirolizumab pegol reduced disease flares in the PHOENYCS GO trial, while enpatoran showed long-term benefits in the WILLOW study. These developments offer hope for more effective SLE treatments, a condition affecting millions worldwide.
Rapid Read Rapid Read
Joyce A. Cramer Honored with Lifetime Accelerator Award for Advancements in Epilepsy Research

Joyce A. Cramer Honored with Lifetime Accelerator Award for Advancements in Epilepsy Research

Joyce A. Cramer has been awarded the Lifetime Accelerator Award by the Epilepsy Foundation of America for her significant contributions to epilepsy therapy development. Cramer, who has had a distinguished career at Yale University School of Medicine, has been instrumental in advancing clinical research in epilepsy. Her work includes pioneering methods for evaluating drug efficacy and adverse effects, as well as strategies to improve medication compliance. She developed the Quality of Life in Epilepsy Inventory and the Seizure Severity Questionnaire, which have provided more nuanced ways to assess seizure characteristics and the impact of therapies. Cramer also served as President and Chief Scientific Officer of the Epilepsy Therapy Project, where she guided entrepreneurs and pharmaceutical companies in developing innovative treatments. Her efforts have accelerated the translation of scientific ideas into therapeutic opportunities for patients with epilepsy.
Rapid Read Rapid Read
Immune Cell Phenotyping Advances Understanding of Disease Biology

Immune Cell Phenotyping Advances Understanding of Disease Biology

Recent advancements in immune cell phenotyping have provided new insights into disease biology, particularly in chronic conditions. Researchers have developed methods to profile plasma membrane order across various immune cell types, revealing distinct cell states that are not detectable through traditional markers. This approach has been applied to study patients with long COVID and chronic lymphocytic leukemia, uncovering unique subsets of natural killer (NK) cells with varying cytotoxic potential and migratory capacity. These findings could lead to new therapeutic strategies and improve our understanding of immune system dysfunction.
Trendline Trendline
SMi Systems and Luminex Collaborate to Enhance Single-Molecule Imaging Technology

SMi Systems and Luminex Collaborate to Enhance Single-Molecule Imaging Technology

SMi Systems and Luminex Collaborate to Enhance Single-Molecule Imaging Technology
Trendline Trendline
Neuropacs Unveils Study on FDA-Approved Imaging Biomarker for Parkinson's Disease

Neuropacs Unveils Study on FDA-Approved Imaging Biomarker for Parkinson's Disease

Neuropacs Unveils Study on FDA-Approved Imaging Biomarker for Parkinson's Disease
Trendline Trendline
Philadelphia Phillies Host ALS Awareness Night with Charity Auction and Special Programming

Philadelphia Phillies Host ALS Awareness Night with Charity Auction and Special Programming

Philadelphia Phillies Host ALS Awareness Night with Charity Auction and Special Programming
Trendline Trendline
Moderna's mRNA Melanoma Vaccine Shows Promising 5-Year Survival Results

Moderna's mRNA Melanoma Vaccine Shows Promising 5-Year Survival Results

Moderna's mRNA Melanoma Vaccine Shows Promising 5-Year Survival Results
Trendline Trendline
Wiley Rein Faces Lawsuit Over Data Breach Impacting Thousands

Wiley Rein Faces Lawsuit Over Data Breach Impacting Thousands

Wiley Rein Faces Lawsuit Over Data Breach Impacting Thousands
TheStreet TheStreet
Goldman Sachs issues warning on AI’s surging power demand

Goldman Sachs issues warning on AI’s surging power demand

Most people never think about where their electricity comes from. You flip a switch, the lights turn on, and a bill shows up once a month. The whole system is built to fade into the background, and for two decades it mostly did. That stretch of calm came with a quiet financial upside. American ...
SB Nation SB Nation
Arkansas center Elmir Džafić transfers to UConn men’s basketball

Arkansas center Elmir Džafić transfers to UConn men’s basketball

UConn continues to add frontcourt depth.